多药耐药基因MDR1在大肠癌的表达及意义  

Clinical singificance of mutidruge resistance gene expression in colorectal carcinoma

作　　者：阴冠程[1] 亓春花[2] 刘君[2] 崔刚[2] 

机构地区：[1]青岛大学医学院,山东青岛266000 [2]泰安市中心医院,山东泰安271000

出　　处：《社区医学杂志》2007年第02S期22-24,共3页Journal Of Community Medicine

摘　　要：目的探讨多药耐药基因(MDR1基因)在大肠癌组织中的表达及其与临床病理的关系。方法应用RT-PCR方法检测了93例手术切除大肠癌组织中的MDR1 mRNA.结果MDR1mRNA的阳性率为37.63%,MDR1基因的表达与年龄、性别、肿瘤大小、组织学类型、淋巴结转移及Dukes分期等无关。结论化疗前大肠癌组织中MDR1基因即存在较高的表达率,且独立于病理形态学之外。提示化疗前要区别对待,对MDR1基因表达阳性者应合理选择化疗。Object To explore the relationship between expression of MDR1 gene in human colorectal carcinoma and clinicopathological changes. Methods From September 2004 to July 2006, a total of 93 consecutive patients with colorectal carcinoma were recruited, and MDR1 mRNA were detected by RT - PCR , Fresh tumor tissues were surgically resected without chemotherapy before operation. Results The positive rate of MDR1 mRNA was 37.63%. The MDR1 gene expression was not significantly correlated with age, sex tumor size, histologic types, lymph node involvment or Dukes stage. Conclusion Because of high expressive level of MDR1 gene in untreated colorectal carcinoma, appropriate chemotherapeutic regimen should be individually chosen for colorectal carcinoma. The expression of MDR1 gene in untreated cancer was independent of morphologic prognostic indexes without correlation between MDR1 gene expression and morphological indexes.

关 键 词：大肠癌 多药耐药基因 逆转录-多聚酶链反应 

分 类 号：R735.34[医药卫生—肿瘤]